One Risk-Reward Profile Investors Should Watch in Biotech Trials
The success of biotech companies and their stocks is often affected by what happens in clinical trials. But how companies design these trials has a big impact on what data they can get out of them.
In this video clip from "The Pharma & Biotech Show," Motley Fool contributor Brian Orelli asks Dr. Frank David, author of The Pharmagellan Guide to Analyzing Biotech Clinical Trials, what investors should look for in biotech studies as it relates to patient population.
Source Fool.com
